Novavax vaccine launch postponed in India: Serum Institute

It has been tested against African and UK variants of C19 and has an overall efficacy of 89% - Serum

89
Medicine Injection Vaccine
Picture: Pixabay

Last Updated on March 29, 2021 by The Health Master

The launch in India of a new C-19 vaccine developed jointly by the Serum Institute of India (SII) and US-based biotech firm Novavax is likely to be delayed to September, said Adar Poonawalla, the CEO of Serum.

He had said in January that the vaccine, named Corovax, was expected to be launched by June.

Poonawalla said the trials of Corovax had kicked off in India, but did not say why the vaccine launch was delayed.

“It has been tested against African and UK variants of C19 and has an overall efficacy of 89%,” tweeted Poonawalla, “Hope to launch by September 2021!”

Enter your email address:

Delivered by FeedBurner

Poonawalla said earlier this month that a temporary US ban on exports of critical raw materials could limit the production of C-19 virus vaccines such as Novavax.

India said on Friday it would prioritise domestic C-19 inoculations amid rising C-19 virus case and had told international buyers of its decision.


Also read:

These 4 Pharma companies invest in ABCD Technologies

MoU for effective implementation of Pharmacovigilance system in India

Pharma exporters to submit reimbursement claims in 3 months

PCI introduces Industry training programme for Pharmacy Teachers

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner